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Effect of dexamethasone on fetal hepatic
glutamine-glutamate exchange
MICHELLE TIMMERMAN,1 CECILIA TENG,2 RANDALL B. WILKENING,2
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1Department of Obstetrics and Gynecology, Erasmus University, 3000 DR Rotterdam, The
Netherlands; and 2Division of Perinatal Medicine, Departments of Pediatrics, Pharmacology,
and Physiology, University of Colorado Health Sciences Center, Denver, Colorado 80262
Timmerman, Michelle, Cecilia Teng, Randall B.
Wilkening, Paul Fennessey, Frederick C. Battaglia, and
Giacomo Meschia. Effect of dexamethasone on fetal hepatic
glutamine-glutamate exchange. Am J Physiol Endocrinol
Metab 278: E839–E845, 2000.—Intravenous infusion of dexa-
methasone (Dex) in the fetal lamb causes a two- to threefold
increase in plasma glutamine and other glucogenic amino
acids and a decrease of plasma glutamate to approximately
one-third of normal. To explore the underlying mechanisms,
hepatic amino acid uptake and conversion of L-[1-13C]gluta-
mine to L-[1-13C]glutamate and 13CO2 were measured in six
sheep fetuses before and in the last 2 h of a 26-h Dex infusion.
Dex decreased hepatic glutamine and alanine uptakes (P ,
0.01) and hepatic glutamate output (P , 0.001). Hepatic
outputs of the glutamate (RGlu,Gln) and CO2 formed from
plasma glutamine decreased to 21 (P , 0.001) and 53% (P 5
0.009) of control, respectively. RGlu,Gln, expressed as a fraction
of both outputs, decreased (P , 0.001) from 0.36 6 0.02 to
0.18 6 0.04. Hepatic glucose output remained virtually zero
throughout the experiment. We conclude that Dex decreases
fetal hepatic glutamate output by increasing the routing of
glutamate carbon into the citric acid cycle and by decreasing
the hepatic uptake of glucogenic amino acids.
fetus; amino acids; fetal liver; placenta
IN THE SHEEP FETUS, THE CONCENTRATION of plasma
cortisol increases before parturition (2), and premature
labor can be induced by infusing glucocorticoids into
the fetal circulation (11). Glucocorticoids also induce
several metabolic changes that are important for sur-
vival after birth, e.g., increased production of lung
surfactant (5) and liver glycogen accumulation (2). A
recent study has shown that the infusion of dexametha-
sone into the circulation of fetal lambs has a remark-
able effect on fetal plasma amino acid concentrations
(1). Several amino acids, e.g., glutamine and alanine,
show a two- to threefold increase in concentration,
whereas plasma glutamate decreases to approximately
one-third of normal. By contrast, plasma serine concen-
tration is virtually unchanged. Analysis of the mecha-
nisms that underlie this complex response may en-
hance our understanding of the hormonal regulation of
fetal amino acid metabolism in the perinatal period.
Previous experiments have demonstrated that, un-
der normal physiological conditions, the fetal liver
takes up glutamine from the fetal circulation (13, 19),
that some of the glutamine taken up is converted to
hepatic glutamate output (19), and that a large fraction
of the glutamate delivered by the liver into the fetal
circulation is taken up and oxidized by the placenta
(14). These observations have led to the hypothesis that
fetal hepatic glutamate output serves two important
functions. The first is to dissociate glucogenic amino
acid oxidation from glucogenesis, thus allowing the
fetus to maintain simultaneously a low rate of glucose
production and a high rate of amino acid oxidation (14).
The second is to contribute to placental glutamate
oxidation, which has been linked to placental NADPH
production and progesterone synthesis (10). At parturi-
tion, these functions are no longer required; therefore,
the decrease in fetal plasma glutamate caused by
dexamethasone (Dex) infusion may be another example
of glucocorticoids coordinating the metabolic changes
that precede birth. The present study was designed to
measure the effect of Dex on fetal plasma glutamine
and glutamate disposal rates and on fetal hepatic
glutamine uptake, as well as its conversion to gluta-
mate and CO2.
MATERIALS AND METHODS
Experimental Design
The studies were approved by the University of Colorado
Health Sciences Center Animal Care and Use Committee. Six
late-gestation mixed-breed Columbia-Rambouillet ewes, each
pregnant with a single fetus, were studied. Surgery was
performed under a combination of general pentobarbital (65
mg/ml) and spinal anesthesia (2 ml 1% pontacaine) after a
48-h fast with free access to water. Preoperatively, each ewe
was given 500 mg of ampicillin and 500 mg of gentamycin
intramuscularly. Polyvinyl catheters were inserted into the
maternal femoral artery and into the uterine vein draining
the pregnant horn, in the fetal aorta via the fetal pedal artery,
the common umbilical vein, and one fetal brachial vein. A left
hepatic venous catheter was placed through a right thora-
cotomy. Fetal muscular tone was reduced by an intravenous
injection of pancuronium (0.3 mg). The catheter was guided
into the left hepatic vein and anchored to its insertion site in
the vena cava. An amniotic catheter was also placed for the
The costs of publication of this article were defrayed in part by the
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injection of antibiotics. All catheters were tunneled subcuta-
neously to a pouch on the ewe’s flank.
After surgery, the animals were allowed free access to
water and alfalfa pellets. On the day of study (5–7 days after
surgery), an infusate solution was prepared containing 100
mg of 99% enriched L-[2,3,3,4,4-2H]glutamate or L-[5D]gluta-
mate, 400 mg of 99% enriched L-[1-13C]glutamine (Cambridge
Isotope Laboratories, Andover, MA), and 400 µCi of tritiated
water (Amersham, Arlington Heights, IL). The L-[1-13C]gluta-
mine was purified before the study to remove any L-[1-13C]-
glutamate that might have been formed during storage. Two
Bio-Rad econo-pac columns (1.5 3 14 cm) were packed 10 cm
in height with 17 ml of Dowex 1 3 8 resin (CL-form, 200–400
mesh). The columns were washed with 20 ml of 10 mM
imidazole buffer pH 7.6 kept on ice. L-[1-13C]glutamine (400
mg) was dissolved in 10 ml of water, and the pH was adjusted
to 7.6 with 1 N NaOH. The glutamine mixture was loaded
onto the columns (5 ml each). The sample front was dis-
carded. The glutamine was eluted three times with 5 ml of
imidazole buffer, pH 7.6, and the total of 15 ml of buffer
fractions was collected on ice and filtered through a 0.2-µm
filter.
Study Protocol
The infusate was given via the fetal brachial vein. The first
4 ml were given as a bolus; the remaining infusate was
administered at a rate of 0.085 ml/min. Beginning at 120 min
and every ,25 min thereafter, four sets of samples were
drawn simultaneously from the maternal femoral artery,
uterine vein, fetal abdominal aorta, umbilical vein, and left
hepatic vein. Maternal and fetal samples were analyzed for
hemoglobin, hematocrit, oxygen saturation, blood gases, triti-
ated water, glucose, lactate, and amino acid concentrations.
In addition, the maternal samples were analyzed for proges-
terone, and the fetal samples were analyzed for 13CO2,
glutamine, and glutamate enrichments. The fetus was trans-
fused with an equal volume of donor blood after each draw.
After the last draw, the infusate was stopped, and 500 mg of
ampicillin were administered via the amniotic catheter. The
next day, water-soluble cyclodextrin-encapsulated dexametha-
sone (Sigma Chemical, St. Louis, MO) was dissolved in
isotonic saline (1.4 mg Dex/100 ml); then, a bolus of 0.2 mg of
Dex was given to the fetus, followed by a continuous infusion
at 0.07 mg/h. After ,26 h of infusion, the same study protocol
was repeated. After completion of this second study period,
the ewe was euthanized. Fetal, placental, uterine, and fetal
liver weights were obtained, and catheter positions were
verified.
Analytical Measurements
Hemoglobin and O2 saturation were measured spectropho-
tometrically (OSM-3, Radiometer, Copenhagen, Denmark).
The blood O2 content was calculated as the product of
hemoglobin content, expressed as O2 capacity times the O2
saturation. Glucose and lactate concentrations were mea-
sured in duplicate with a glucose-lactate analyzer (YSI model
2700 Select and Dual Standard). Plasma 3H2O was measured
on triplicate aliquots in a scintillation counter and converted
to blood 3H2O on the basis of the hematocrit measurement
(18). Respiratory gas tensions and pH were measured with an
ABL330 Radiometer. Total CO2 concentration in blood was
calculated by using the Henderson-Hasselbach equation and
a nomogram from Van Slyke and Sendroy (17). 13CO2 enrich-
ment was measured in samples of 0.5 ml of whole blood,
which were collected in exutainers (Metabolic Solutions) and
analyzed by means of tandem gas chromatography-isotope
radio mass spectrometry.
Progesterone was measured using a validated (3) Coat-a-
count progesterone RIA kit (Diagnostic Product, Los Angeles,
CA). Inter- and intra-assay coefficients of variation (CV, %) for
the low-quality control were 9.23 and 6.02%, respectively, and
for the high-quality control were 6.69 and 3.44%, respectively.
Plasma samples for amino acid concentrations were stored
at 270°C until the day of analysis. At that time, the samples
were thawed quickly and deproteinized with 15% sulfosali-
cylic acid containing 300 µM norleucine as internal standard.
The pH was adjusted to 2.2 with 1.5 N LiOH. After centrifuga-
tion, the supernatant was analyzed with a Dionex HPLC
amino acid analyzer (Dionex, Sunnyvale, CA). The same
column was used for all samples from an individual animal.
Reproducibility within the same column was 62%. Samples
from all vessels drawn simultaneously were loaded to run
within 12 h. Amino acid absorbencies were measured after
reaction with ninhydrin at 570 nm, except proline, which was
measured at 440 nm wavelength.
For mass spectrometry, amino acids were first separated on
,0.2 ml of AG-50 3 8 (BioRA mesh 100–200) cation exchange
resin. Plasma (0.4 ml fetal arterial and umbilical venous, 0.25
ml hepatic venous) was mixed with 50% acetic acid and
applied to the column. After the resin was washed, the amino
acids were eluted with 2 3 500 µl of NH4OH and lyophilized.
Tert-butyldimethylsilyl ether derivatives were formed by
adding 200 µl acetonitrile containing 15% N-methyl-N(t-
butyldimethylsilyl)trifluoroacetamide and 1.5% t-butyldimeth-
ylchlorosilane and heating at 100°C for 30 min. Tandem gas
chromatography-mass spectrometry was performed on a HP-
5790 gas chromatograph mass spectrometer with a 30-m DB
1 0.025-mm ID 0.25-µm film thickness fused silica capillary
column with helium as the carrier gas (velocity, 40 cm/s). The
selected conditions for glutamate and glutamine were an
injection port and T-line temperature of 280°C, and oven
temperature programmed from 100 to 320°C at a rate of
10°C/min. This resulted in a glutamate m-57 peak at ,13 min
and a glutamine m-57 peak at ,14 min. The ion clusters
monitored were mass-to-charge ratios (m/z) 432, 433, 434,
435, 436, and 437 for glutamate and 431, 432, 433, 434, 435,
and 436 for glutamine. The enrichments were calculated by
using the increase in the isotope peaks after correction for the
natural abundance.
Calculations
A schematic drawing of the fetoplacental circulation show-
ing the position of the fetal catheters has been published (19).
Reference to this drawing clarifies the rationale of the
following calculations.
Blood flows and uptakes. Umbilical blood flow (Qf) was
measured by application of the steady-state transplacental
diffusion method, using tritiated water as the flow indicator
(18). The umbilical uptakes of oxygen, glucose, and lactate
were calculated by application of the Fick principle
umbilical uptake 5 Qf(g 2 a)blood
where g and a refer to umbilical venous and umbilical arterial
blood concentrations, respectively.
Umbilical uptakes of amino acids were calculated using
plasma flows and plasma concentrations as follows
umbilical uptake 5 Qf(1 2 Ht)(g 2 a)plasma
where Ht is the fractional hematocrit. The use of plasma flows
is based on evidence that, in sheep, the rapid amino acid
exchange between circulating blood and body tissues is
virtually limited to an exchange between the tissues and the
plasma compartment (4).
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Hepatic uptake of metabolic substrates was normalized for
hepatic O2 uptake by calculating the substrate to O2 uptake
molar ratio. This required calculation of the ratio
(hi 2 h) 4 (hi 2 h)O2
where hi represents the concentration of substrate at the
hepatic input, and h represents the directly measured sub-
strate concentration in the left hepatic vein.
The fetal left hepatic lobe is perfused by fetal arterial and
umbilical venous blood, with the umbilical venous blood
making a .80% contribution (6). In each fetus, the fractional
contribution of umbilical venous blood (FV) to total left
hepatic blood flow was calculated (19) as
Fv 5 (CT,H 2 CT,a) 4 (CT,g 2 CT,a)
where CT,h, CT,a, and CT,g represent the tritiated water concen-
trations (dpm/ml) in the fetal hepatic venous, fetal arterial,
and umbilical venous blood, respectively.
Hepatic input concentrations of metabolic substrates (Chi)
were then calculated using the equation
Chi 5 (Fv 3 Cg) 1 (Fa 3 Ca)
where Fa is the fractional arterial contribution to left hepatic
flow (Fa 5 1 2 Fv), and Ca and Cg are the substrate
concentrations in the umbilical arterial and venous blood.
The hepatic amino acid (AA)-to-oxygen uptake molar ratio
was calculated as
AA uptake 4 O2 uptake 5 {[(Chi 2 Ch)AA]
3 (1 2 Ht)]} 4 (Chi 2 Ch)O2
Disposal rates. The fetal plasma glutamine and glutamate
disposal rates (DR) were calculated as
DR 5 [100 4 MPEa) 2 1] 3 C 3 I
where MPEa is the fetal arterial plasma molar percent
enrichment of tracer at steady state, C is the concentration of
the tracer in the infusate (µmol/ml), and I is the infusion rate
(ml/min). For the deuterium-labeled glutamate, I represents
the 2H412H5 infusion rate, and MPEa represents 2H412H5
MPE. This equation does not correct for any unlabeled
glutamine or glutamate present in the infusate; however,
both [1-13C]glutamine and [2H412H5]glutamate accounted for
.95% of the total glutamine and glutamate infused.
Tracer glutamine and glutamate concentrations. Plasma
tracer glutamine and glutamate concentrations were calcu-
lated as total plasma concentrations times their respective
MPEs divided by 100.
Hepatic conversion of plasma glutamine to hepatic gluta-
mate and CO2 output. The hepatic output of glutamate
formed from plasma glutamine (RGlu,Gln), expressed as a
substrate output-to-O2 uptake ratio, was calculated by using
the plasma concentration difference of L-[1-13C]glutamate
across the hepatic circulation, (Ch 2 Chi)13-Glu, and the percent
enrichment of L-[1-13C]glutamine at the hepatic input,
(MPEhi)13-Gln, according to the equation
RGlu,Gln 5 100 3 (Ch 2 Chi)13-Glu 3 (1 2 Ht) 4 (Chi 2 Ch)O2
4 (MPEhi)13-Gln
The output of CO2 formed from C-1 of plasma glutamine
(RCO2,Gln), was similarly calculated, using the whole blood
concentration difference of 13CO2, (Ch 2 Chi)13CO2
RCO2,Gln 5 100 3 (Ch 2 Chi)13-CO2 4 (Chi 2 Ch)O2 4 (MPEhi)13-Gln
Statistics
Differences between study periods were tested using Stu-
dent’s t-test for paired samples. Two-sided P values were
considered significant at P , 0.05. Linear regressions were
calculated by the least squares method.
RESULTS
Table 1 presents mean gestational age, fetal, placen-
tal, and fetal liver weights, uterine and umbilical blood
flows, and oxygen uptakes for the six sheep. Fetal
hematocrit and hemoglobin and the blood oxygen con-
tent differences across the umbilical and left hepatic
circulations increased after Dex infusion. In addition,
there was an increase in uterine blood flow that was
accompanied by an increase in umbilical venous oxygen
saturation. The fractional contribution of umbilical
venous blood to left hepatic blood flow (Fv) was 0.91 and
0.97, respectively, in two of the six fetuses and not
significantly different from 1.0 in the other four.
Glucose and Lactate Concentrations and Uptakes
During fetal Dex infusion, there were significant in-
creases in the concentrations of maternal plasma glucose,
fetal plasma glucose, and lactate. Concomitant with these
changes, there was a significant increase in umbilical
lactate uptake. Hepatic glucose uptake was virtually zero
in both the control and the experimental period, and hep-
atic lactate uptake did not increase significantly (Table 2).
Amino Acid Concentration, Uptakes, and Fluxes
Dex infusion caused a large increase in fetal plasma
glutamine (Table 3). In two of the six fetuses, the
Table 1. Gestational age, fetal, fetal hepatic and
placental weights, umbilical and uterine blood flows,
fetal hematocrits, blood O2 capacities and saturations,
O2 content differences across umbilical and left hepatic
circulations, and umbilical and uterine O2 uptakes in 6
sheep before and during fetal dexamethasone infusion
Gestational age, days 12761
Fetal weight, g 2,851681
Fetal liver weight, g 102610
Placental cotyledons weight, g 333631
Control
Dexa-
methasone P
Blood flows, ml·min21 ·kg fetus21
Umbilical 250620 221625 NS
Uterine 479653 573648 0.03
Blood hematocrit, % 3262 3562 0.02
Blood O2 capacity, mM 5.4660.3 5.9760.3 ,0.001
Blood O2 saturations, %
Umbilical artery 50.163.0 54.462.4 NS
Umbilical vein 78.262.4 86.561.5 0.01
Left hepatic vein 68.962.5 73.061.7 NS
Blood O2 content differences, mM
Across umbilical circulation 1.456 .09 1.756 .13 0.014
Across left hepatic lobe circulation 0.446 .05 0.606 .04 0.002
O2 uptakes, µmol ·min21 ·kg fetus21
Umbilical 353613 373625 NS
Uterine 668647 613644 NS
Values are means 6 SE. NS, not significant.
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glutamine increase was very large and could not be
measured under the conditions that allowed chromato-
graphic analysis of all the other amino acids. Concomi-
tant with the increase in plasma glutamine, there was
a significant increase in the disposal rate of plasma
glutamine, a decrease in hepatic glutamine uptake,
and no significant change in umbilical glutamine up-
take (Table 3).
In contrast to glutamine, the fetal plasma concentra-
tion of glutamate decreased significantly. This decrease
was accompanied by a decrease in the plasma gluta-
mate disposal rate and a decrease in both hepatic
glutamate output and placental uptake of fetal gluta-
mate (Table 3). The hepatic output and the placental
uptake of glutamate were significantly correlated (r 5
0.87).
The constant infusion of glutamine and glutamate
tracers into the fetal circulation resulted in steady-
state plasma enrichments of the infused tracers and
their metabolic products (Fig. 1). The infusion of L-[1-13C]-
glutamine produced a relatively large L-[1-13C]gluta-
mate enrichment in the fetal circulation. The arterial
glutamate-to-glutamine enrichment ratios were 0.30 6
0.02 and 0.35 6 0.05 in the control and the experimen-
tal periods, respectively. These two ratios were not
significantly different (P . 0.1). The infusion of [5D]glu-
tamate produced a very small deuterium enrichment of
plasma glutamine. The arterial glutamine-to-gluta-
mate enrichment ratio was 0.02 6 0.007 in the control
period and decreased significantly (P , 0.05) to 0.007 6
0.002 during Dex infusion.
There was no detectable difference in plasma gluta-
mine enrichment between left hepatic input and he-
patic vein, during both the control and experimental
periods, thus indicating that at steady state, the gluta-
mine flux into the liver was virtually equal to hepatic
glutamine uptake. The hepatic glutamine uptake was
accompanied by hepatic output of glutamate formed
from glutamine (RGlu,Gln) and by hepatic output of CO2
derived from the C-1 carbon of glutamine (RCO2,Gln). These
two outputs accounted for virtually all of the glutamine up-
take, i.e., the (RGlu,Gln 1 RCO2,Gln) sum was not significantly
different from hepatic glutamine uptake. Both RGlu,Gln
and RCO2,Gln decreased significantly in response to Dex
(Table 3). However, the decrease in glutamate output was
relatively greater than the decrease in CO2 output. The
contribution of RGlu,Gln to the combined (RGlu,Gln 1 RCO2,Gln)
output was 36 6 2% in the control period and decreased
significantly to 18 6 4% in the experimental period, (P
0.001) (Table 3).
Several neutral amino acids shared the response of
glutamine to Dex infusion. Eight amino acids (threo-
nine, asparagine, proline, glycine, alanine, isoleucine,
Table 2. Glucose and lactate concentrations and
uptakes in six sheep before and during fetal
dexamethasone infusion
Control Dexamethasone P
Plasma glucose con-
centrations, mM
Maternal artery 4.266 .11 5.246 .05 ,0.001
Umbilical artery 1.256 .08 2.276 .19 ,0.001
Umbilical vein 1.4360.8 2.456 .17 ,0.001
Fetal left hepatic
vein 1.426 .07 2.456 .18 ,0.001
Plasma lactate con-
centrations, mM
Umbilical artery 2.226 .29 4.506 .34 ,0.005
Umbilical vein 2.316 .31 4.716 .34 ,0.005
Fetal left hepatic
vein 2.156 .29 4.376 .32 ,0.005
Umbilical uptakes,
µmol ·min21 ·kg
fetus21
Glucose 38.263.0 31.463.2 NS
Lactate 29.162.3 44.364.8 0.05
Hepatic uptake to O2
uptake molar
ratios
Glucose 20.016 .03 20.016 .03 NS
Lactate 0.366 .07 0.476 .04 NS
Values are means 6 SE.
Table 3. Fetal glutamine and glutamate
concentrations, uptakes, and fluxes before
and during fetal dexamethasone infusion
Control Dexamethasone P
Glutamine
Plasma concentrations
(µgM)
Umbilical artery (a) 431622 1,1516129* 0.011
Umbilical vein (g) 477625 1,2036124* 0.011
Left hepatic input (hi) 476625 1,2036124* 0.011
Left hepatic vein (h) 381632 1,1526132* 0.010
Umbilical uptake, µmol ·
min21 ·kg fetus21 7.461.0 7.761.4* NS
Disposal rate, µmol ·
min21 ·kg fetus21 21.461.5 32.761.8 ,0.001
Hepatic uptake to O2
uptake ratio, µmol/
mmol 150615 5366* 0.01
Glutamate
Plasma concentrations
(µM)
Umbilical artery (a) 47.268.2 17.065.1 0.001
Umbilical vein (g) 9.461.9 1.360.4 0.008
Left hepatic input (hi) 9.961.8 1.460.4 0.008
Left hepatic vein (h) 108.8617.9 58.3617.4 0.008
Umbilical uptake, µmol ·
min21 ·kg fetus21 26.160.6 22.160.7 ,0.001
Disposal rate, µmol ·
min21 ·kg fetus21 9.660.8 5.660.5 ,0.001
Hepatic fluxes to O2 uptake
ratios, µmol/mmol
Uptake 2150619 258617 ,0.001
Output of glutamate
formed from plasma
glutamine (RGlu,Gln) 5367 1162 ,0.001
Output of CO2 formed
from C1 of plasma glu-
tamine (RCO2,Gln) 95614 5064 0.009
RGlu,Gln 4 (RCO2,Gln
1RGlu,Gln) 0.3660.02 0.1860.04 0.001
Values are means 6 SE; *n 5 4. RGlu,Gln, hepatic output of
glutamate (Glu) formed from glutamine (Gln); RCO2,Gln, hepatic
output of CO2 derived from C-1 carbon of glutamine.
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tyrosine, and phenylalanine) demonstrated a signifi-
cant increase in plasma concentration, and three of
these (threonine, glycine, and alanine) also demon-
strated a significant decrease in hepatic uptake (Table
4). By contrast, serine, the amino acid which, in addi-
tion to glutamate, is released by the fetal liver into the
fetal circulation, showed no significant changes in
concentration and hepatic output (Table 4).
Progesterone Output by the Pregnant Uterus
The output of progesterone into the uterine circula-
tion (calculated as the uterine plasma flow times plasma
progesterone venous-arterial concentration difference
across the uterus) decreased significantly (P , 0.01)
with Dex infusion from 21 6 3 to 3 6 2 nmol·min21 ·kg
fetus21.
DISCUSSION
The present study provides the first demonstration
that the flux of L-[1-13C]glutamine into the fetal liver is
virtually equal to the sum of L-[1-13C]glutamate and
13CO2 hepatic output (Table 3). This finding implies
that most of the plasma glutamine taken up by the fetal
liver is converted to glutamate, which is then utilized in
two different ways: some is excreted into the fetal
circulation, and some is routed into the citric acid cycle
via deamination to a-ketoglutarate and subsequent
oxidative decarboxylation to form succinyl-CoA. It also
Fig. 1. Fetal plasma enrichments of L-[1-13C]glutamine
(A), L-[5D]glutamate (B), and L-[1-13C]glutamate (C)
during both study days. Enrichments on the y-axis are
in units of molar percent enrichment.
Table 4. Fetal arterial concentrations and umbilical and hepatic uptakes of amino acids in the control period (C)
and during fetal dexamethasone infusion (D)
Plasma
Concentration, µM
Umbilical Uptake,
µmol ·min21 ·kg fetus21
Hepatic Uptake,
µmol/mmol O2
C D C D C D
Asp 1464 963 20.260.1 0.060.1 2161 20.760.8
Thr 284635 536651† 3.760.3 2.460.6 4262 2664†
Ser 641644 569645 21.260.6 21.561.1 24768 251611
Asn 4669 10867‡ 1.660.3 0.760.5 1963 665
Pro 135618 346638‡ 2.160.8 0.760.8 1167 0611
Gly 404626 757663† 4.160.5 3.160.8 4867 2766*
Ala 280621 837675‡ 3.260.3 1.360.8* 72610 2166†
Val 531659 587666 5.760.4 5.961.3 1864 1467
Met 70612 89612 1.060.5 0.860.2 1365 1063
Ile 122615 161617* 2.860.3 3.660.4 861 861
Leu 179622 219640 4.660.4 4.760.8 1761 1765
Tyr 107611 163614† 1.860.3 1.760.2 2663 3065
Phe 8866 183618† 1.760.1 1.660.2 2261 2464
Values are means 6 SE. *P , .05; †P , .01; ‡P , .001.
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implies that the direct flux of plasma glutamine into
hepatic protein synthesis is relatively small in compari-
son with the other routes of hepatic disposal.
Dexamethasone infusion caused a decrease in the
fetal hepatic glutamate output-to-oxygen uptake ratio
to 35% of control (Table 3). Although some of this
change could be due to an increase in hepatic oxygen
uptake, it is important to note that the decrease in the
ratio was accompanied by comparable percent de-
creases in fetal arterial glutamate concentration and in
the placental uptake of fetal glutamate, as well as a
significant (P , 0.001) decrease in the fetal plasma
glutamate disposal rate from 9.6 6 0.8 to 5.6 6 0.5
µmol·min21 ·kg fetus21 (Table 3). Therefore, we can
conclude that the decrease in the hepatic glutamate
output-to-oxygen uptake ratio represents primarily a
decrease in hepatic glutamate output.
Knowledge that glucocorticoids increase the activity
of hepatic glucogenic enzymes in the fetal lamb (2)
leads to the hypothesis that dexamethasone decreases
fetal hepatic glutamate output because the glutamate
produced by the liver is diverted into the glucogenic
pathway. More specifically, it leads to the hypothesis
that a larger fraction of the glutamate formed from the
hepatic glutamine uptake enters the citric acid cycle.
The present study agrees with this hypothesis by
showing that dexamethasone decreased significantly
the RGlu,Gln-to-(RGlu,Gln 1 RCO2,Gln) ratio from 0.36 6 0.02
to 0.18 6 0.04 (Table 3).
The study also establishes that a decrease in the
hepatic uptakes of glutamine and alanine was an
additional mechanism for the decreased hepatic gluta-
mate output (Tables 3 and 4). Given the large increase
in plasma glutamine and alanine concentrations dur-
ing dexamethasone infusion, direct evidence for changes
in glutamine and alanine uptake rests on the measure-
ment of relatively small changes in the extraction of the
two amino acids across the hepatic circulation. Hepatic
glutamine extraction declined from 20 to 4% instead of
decreasing to the 11% predicted by a constant hepatic
glutamine-to-oxygen uptake ratio. Similarly, alanine
extraction declined from 17 to 2% instead of decreasing
to 8%. Because these small changes cannot be mea-
sured precisely, it is important to note that dexametha-
sone caused the hepatic output of CO2 formed from plasma
glutamine, (RCO2,Gln), to decrease significantly to 53% of
control and that the change in the (RGlu,Gln 1 RCO2,Gln)
sum was approximately equal to the estimated change
in hepatic glutamine uptake (287 vs. 297 µmol/mmol
oxygen). Therefore, a decrease in fetal hepatic gluta-
mine uptake is confirmed by the decrease in the
combined output of its two major metabolic products.
The finding that dexamethasone decreases fetal he-
patic glutamine and alanine uptake is contrary to
evidence in adult mammals. In fasting dogs, dexametha-
sone has no detectable effect on glutamine uptake by
the liver and increases hepatic alanine uptake (16). In
rats, dexamethasone stimulates sodium-dependent glu-
tamine uptake via system N transporters by cultured
hepatocytes and by sinusoidal membrane vesicles iso-
lated from liver homogenates (7). Developmental
changes in the effect of dexamethasone on amino acid
transport and metabolism have been previously noted.
In newborn babies (15, 20) and in newborn rats (8),
dexamethasone infusion causes a marked increase in
the plasma concentration of several amino acids, gluta-
mine and alanine included, whereas in adult men (21),
it causes no significant concentration changes, with the
exception of a small increase in alanine. In contrast to
hepatocytes isolated from adult rats, fetal rat hepato-
cytes do not respond to dexamethasone with an in-
crease in system A-mediated transport (9). In vivo data
do not provide the detailed information that is needed
to establish whether the inhibitory effect of dexametha-
sone on fetal hepatic glutamine and alanine uptakes
represents inhibition of amino acid transport into the
liver or downregulation of amino acid metabolism
within the liver. Furthermore, we cannot exclude the
possibility that the dexamethasone effect on hepatic
amino acid uptake was indirect via some other hor-
monal or metabolic change caused by the dexametha-
sone infusion. At the time the measurements were
made, i.e., 26 h after starting dexamethasone infusion,
there was no evidence for the net increase in either
hepatic lactate uptake and/or glucogenic amino acid
carbon uptake that one would expect if the hormone
stimulated rapid glycogen deposition (2). We cannot
exclude the possibility that glycogen had been accumu-
lating more rapidly at an earlier stage of dexametha-
sone stimulation or that the dose and potency of the
glucocorticoid determine whether glycogen accumula-
tion or inhibition of glucogenic amino acid uptake
predominates. The rationale for studying the effect of
dexamethasone at 26 h was based on a previous study
(1) showing that 3 h after starting the dexamethasone
infusion (0.2 mg bolus followed by 0.07 mg/h), there
were no significant changes in fetal plasma glutamine,
glutamate, glucose, and lactate concentrations, whereas
marked changes in the concentrations of these metabo-
lites were present at 25 h. The dose of dexamethasone
used in the present and previous studies was selected
because it may produce some of the metabolic changes
associated with parturition; it decreases progesterone
output by the pregnant uterus and it has been shown to
induce premature labor ,56 h after the start of the
infusion.
With dexamethasone infusion, the disposal rate of
fetal plasma glutamine increased significantly. This
indicates that, in contrast to the liver, elsewhere in the
fetus, the glutamine flux from plasma to tissues had
increased. Part of the increased flux may represent
increased interorgan exchange. In dogs, dexametha-
sone increases glutamine release by skeletal muscle
and glutamine uptake by gut and kidney (16).
In sheep, glucocorticoids play an important role in
stimulating the metabolic changes that initiate parturi-
tion and adapt the lamb to postnatal life (2, 5, 11).
Decreasing the glutamate supply to the placenta and
diverting glutamate carbon into glucogenesis may rep-
resent additional aspects of this role. During parturi-
tion, glucocorticoids cause a decrease in progesterone
synthesis by the placenta. This change may entail a
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decrease in glutamate oxidation by placental mitochon-
dria (10) and a decrease in placental glutamate require-
ments. It would appear that glucocorticoids serve the
dual function of reducing placental glutamate require-
ments and the supply of glutamate to the placenta by
the fetal liver.
Stimulation of fetal hepatic glucogenesis by glucocor-
ticoids is indicated by the findings that cortisol in-
creases the activity of hepatic glucogenic enzymes and
hepatic glycogen storage (2) and that dexamethasone
diverts glutamate carbon from hepatic output to flux
into the citric acid cycle. However, dexamethasone
infusion into the fetus decreases the hepatic uptake of
glucogenic amino acids and does not induce hepatic
glucose output. The functional meaning of these seem-
ingly contradictory effects is obscure. Studies of fetal
amino acids and carbohydrate metabolism during spon-
taneous parturition are needed for a better understand-
ing of the relevance of fetal glucocorticoid infusion
experiments to normal physiology. It should be noted
that a glucocorticoid, betamethasone, is used in preg-
nant patients to stimulate pulmonary maturation in
the human fetus. Although the original usage had been
confined to a single dose given shortly before antici-
pated delivery, currently it may be given in repeated
doses some weeks before delivery. We hypothesize that
the changes in fetal glucogenic amino acid concentra-
tion and metabolism found in the present study might
also occur in this clinical situation.
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